-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 8, CDE's official website showed that a clinical application for the new class 1 drug ,TQC3721 mixed suspension for inhalation was accepted.
the drug is a new class 1 drug in the field of breathing.
Insight database shows that the current day clear has been listed in the product to anti-infective drugs mainly, in the research products to anti-tumor drugs mainly, in addition to these two areas, respiratory drugs are also a major force in the field of day clear.
from the Insight database (), there are currently 2 main varieties of new class 1 drugs in the respiratory field under development, TQC3721 and TQC3564.
the former for obstructive pulmonary disease and asthma, while the latter for asthma, allergic rhinitis and allergic rhinitis.
TQC3721, which is currently clinically declared, has not disclosed any other information other than adaptation.
another new drug, TQC3564, was approved for clinical use in 2019 Q3, and 2020 Q3 completed Phase 1 clinical, which has not yet been initiated.
details of the TQC3564 project